相关实验视频

Updated: Jan 17, 2026

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts

Published on: February 23, 2024

血清费里丁作为PEG IFNα-2b在慢性乙型肝炎治疗中的疗效预测生物标志物

Meiya Chen^1,2, Chenhao Wang¹, Miqiang Lin¹

¹The Graduate School of Fujian Medical University, Fuzhou, China.

Frontiers in cellular and infection microbiology

|September 24, 2025

概括

血清费里丁水平预测了在接受PEGylated干扰素α-2b (PEG IFNα-2b) 的慢性乙型肝炎 (CHB) 患者的治疗成功. 较高的基线费里表明对CHB的PEG IFNα-2b治疗有更好的反应.

科学领域:

肝病学肝病学是一种肝病学.
病毒学病毒学
生物标志物发现发现

背景情况:

慢性乙型肝炎 (CHB) 构成了全球重大健康挑战,导致肝脏持续炎症.
虽然PEGylated干扰素α-2b (PEG IFNα-2b) 提供了比口服抗病毒药物更高的功能治愈率,但选择最佳候选者至关重要.
确定可靠的PEG IFNα-2b疗效生物标志物对于个性化CHB治疗策略至关重要.

研究的目的:

评估血清费里丁作为PEG IFNα-2b治疗疗效的预测生物标志物. 在CHB患者中.
为了确定基线血清费里水平和治疗结果之间的相关性.
通过多变量逻辑回归和ROC曲线分析,评估血清费里丁的独立预测值.

主要方法:

血清费里丁,HBsAg和转氨酶水平在CHB患者中被监测,在基线,12周和24周接受PEG IFNα-2b治疗.
根据24周和48周的HBsAg降低,患者被分为有效和无效组.
使用多变量逻辑回归和ROC曲线分析来评估费里的预测值,控制混因素.

主要成果:

在CHB患者的PEG IFNα-2b治疗期间,血清费里水平增加.
在有效治疗组中,与无效治疗组相比,观察到显著更高的血清费里水平.
血清费里丁被证实是PEG IFNα-2b疗效的独立预测因子,具有高预测价值,ROC分析表明.

结论:

血清费里水平与PEG IFNα-2b的抗肝炎B病毒疗效密切相关.
血清费里丁显示出作为指导CHB治疗的可靠和经济的生物标志物的潜力.
利用血清费里丁可以帮助优化治疗策略,并改善接受PEG IFNα-2b的CHB患者的治疗结果.

关键词:

这就是ALT ALT.这就是HBsAg.在 PEG IFN-α2bb 中.慢性乙型肝炎慢性乙型肝炎血清费里氨酸的使用情况

更多相关视频

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...